Najlah M, Said Suliman A, Tolaymat I, Kurusamy S, Kannappan V, Elhissi A et al. Development of Injectable PEGylated Liposome Encapsulating Disulfiram for Colorectal Cancer Treatment. Pharmaceutics. 2019;11(11):610.

Butcher K, Kannappan V, Kilari R, Morris M, McConville C, Armesilla A et al. Investigation of the key chemical structures involved in the anticancer activity of disulfiram in A549 non-small cell lung cancer cell line. BMC Cancer. 2018;18(1).

Xu B, Wang S, Li R, Chen K, He L, Deng M et al. Disulfiram/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and inhibition of NF-κB and Nrf2. Cell Death & Disease. 2017;8(5):e2797-e2797.

Najlah M, Ahmed Z, Iqbal M, Wang Z, Tawari P, Wang W et al. Development and characterisation of disulfiram-loaded PLGA nanoparticles for the treatment of non-small cell lung cancer. European Journal of Pharmaceutics and Biopharmaceutics. 2017;112:224-233.

Wang Z, Tan J, McConville C, Kannappan V, Tawari P, Brown J et al. Poly lactic-co-glycolic acid controlled delivery of disulfiram to target liver cancer stem-like cells. Nanomedicine: Nanotechnology, Biology and Medicine. 2017;13(2):641-657.

Kannappan D, Wang D, Liu D, Brown D, Butcher M, Azar M et al. PP54. NANO-ENCAPSULATED DISULFIRAM TARGETS GLIOBLASTOMA STEM CELLS IN VITRO AND IN VIVO BY MODULATION OF HYPOXIA-NF-KB PATHWAY. Neuro-Oncology. 2017;19(suppl_1):i15-i15.

Zhao H, Shi P, Deng M, Jiang Z, Li Y, Kannappan V et al. Low dose triptolide reverses chemoresistance in adult acute lymphoblastic leukemia cells via reactive oxygen species generation and DNA damage response disruption. Oncotarget. 2016;7(51):85515-85528.

Kannappan V, Butcher K, Trela M, Nicholl I, Wang W, Attridge K. Interleukin 21 inhibits cancer-mediated FOXP3 induction in naïve human CD4 T cells. Cancer Immunology, Immunotherapy. 2017;66(5):637-645.

Deng M, Jiang Z, Li Y, Zhou Y, Li J, Wang X et al. Effective elimination of adult B-lineage acute lymphoblastic leukemia by disulfiram/copper complex in vitro and in vivo in patient-derived xenograft models. Oncotarget. 2016;7(50):82200-82212.

Tawari P, Wang Z, Najlah M, Tsang C, Kannappan V, Liu P et al. The cytotoxic mechanisms of disulfiram and copper(ii) in cancer cells. Toxicology Research. 2015;4(6):1439-1442.

McConville C, Tawari P, Wang W. Hot melt extruded and injection moulded disulfiram-loaded PLGA millirods for the treatment of glioblastoma multiforme via stereotactic injection. International Journal of Pharmaceutics. 2015;494(1):73-82.

Liu P, Kumar I, Brown S, Kannappan V, Tawari P, Tang J et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. British Journal of Cancer. 2013;109(7):1876-1885.

Li Y, Chen K, Zhou Y, Xiao Y, Deng M, Jiang Z et al. A New Strategy to Target Acute Myeloid Leukemia Stem and Progenitor Cells Using Chidamide, a Histone Deacetylase Inhibitor. Current Cancer Drug Targets. 2015;15(6):493-503.

Zembko I, Ahmed I, Farooq A, Dail J, Tawari P, Wang W et al. Development of Disulfiram-Loaded Poly(Lactic-co-Glycolic Acid) Wafers for the Localised Treatment of Glioblastoma Multiforme: A Comparison of Manufacturing Techniques. Journal of Pharmaceutical Sciences. 2015;104(3):1076-1086.

Baffoe C, Nguyen N, Boyd P, Wang W, Morris M, McConville C. Disulfiram-loaded immediate and extended release vaginal tablets for the localised treatment of cervical cancer. Journal of Pharmacy and Pharmacology. 2014;67(2):189-198.

Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang Y et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway inhibition. Journal of Translational Medicine. 2014;12(1):163.

Boyd P, Major I, Wang W, McConville C. Development of disulfiram-loaded vaginal rings for the localised treatment of cervical cancer. European Journal of Pharmaceutics and Biopharmaceutics. 2014;88(3):945-953.

Liu P, Wang Z, Brown S, Kannappan V, Tawari P, Jiang W et al. Liposome encapsulated Disulfiram inhibits NFκB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget. 2014;5(17):7471-7485.

Liu P, Brown S, Goktug T, Channathodiyil P, Kannappan V, Hugnot J et al. Cytotoxic effect of disulfiram/copper on human glioblastoma cell lines and ALDH-positive cancer-stem-like cells. British Journal of Cancer. 2012;107(9):1488-1497.

Wang W, Darling J. How could a drug used to treat alcoholism also be effective against glioblastoma?. Expert Review of Anticancer Therapy. 2013;13(3):239-241.

Xu B, Shi P, Fombon I, Zhang Y, Huang F, Wang W et al. Disulfiram/copper complex activated JNK/c-jun pathway and sensitized cytotoxicity of doxorubicin in doxorubicin resistant leukemia HL60 cells. Blood Cells, Molecules, and Diseases. 2011;47(4):264-269.

Yip N, Fombon I, Liu P, Brown S, Kannappan V, Armesilla A et al. Disulfiram modulated ROS–MAPK and NFκB pathways and targeted breast cancer cells with cancer stem cell-like properties. British Journal of Cancer. 2011;104(10):1564-1574.

Xu B, Guo X, Mathew S, Armesilla A, Cassidy J, Darling J et al. Triptolide simultaneously induces reactive oxygen species, inhibits NF-κB activity and sensitizes 5-fluorouracil in colorectal cancer cell lines. Cancer Letters. 2010;291(2):200-208.

Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla A et al. Disulfiram/copper complex inhibiting NFκB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Letters. 2010;290(1):104-113.

Wang W, McLeod H, Cassidy J. Disulfiram-mediated inhibition of NF-kB activity enhances cytotoxicity of 5-fluorouracil in human colorectal cancer cell lines. International Journal of Cancer. 2003;104(4):504-511.